Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
prostaglandin analog |
| gptkbp:approvedBy |
2001 (US)
|
| gptkbp:ATCCode |
S01EE04
|
| gptkbp:brand |
gptkb:Travatan
gptkb:Travatan_Z |
| gptkbp:CASNumber |
157283-68-6
|
| gptkbp:developedBy |
gptkb:Alcon
|
| gptkbp:eliminationHalfLife |
45 minutes (in plasma)
|
| gptkbp:hasMolecularFormula |
C26H35F3O6
|
| https://www.w3.org/2000/01/rdf-schema#label |
travoprost
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
increases outflow of aqueous humor
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
ophthalmic
|
| gptkbp:sideEffect |
eye irritation
eye redness darkening of iris color increased eyelash growth |
| gptkbp:usedFor |
treatment of ocular hypertension
treatment of open-angle glaucoma |
| gptkbp:bfsParent |
gptkb:Travatan
|
| gptkbp:bfsLayer |
5
|